Holdings of Aisling Capital Management LP
11 declared positions · as of Mar 31, 2026
Original filing · Ten largest lines: 99.9 % of the equity sleeve
Sector breakdown
- Unattributed 100.0 %
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
- USD 100.0 %
The quoted currency of each line, as declared.
Country breakdown
- US 98.3 %
- GB 1.7 %
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | US | 10 | 464.1M $ | 98.32 % |
| 2 | GB | 1 | 7.9M $ | 1.68 % |
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Bridgebio Pharma Inc | 5,089,611 | 378M $ | |
| 2 | Syndax Pharmaceuticals Inc | 1,316,806 | 30.8M $ | |
| 3 | Monte Rosa Therapeutics Inc | 1,555,664 | 25.6M $ | |
| 4 | Bicara Therapeutics Inc | 568,919 | 11.3M $ | |
| 5 | BridgeBio Oncology Therapeutics Inc | 1,018,018 | 9.1M $ | |
| 6 | Compass Pathways plc | 1,432,336 | 7.9M $ | |
| 7 | Scholar Rock Holding Corp | 77,031 | 3.8M $ | |
| 8 | BIOMEA FUSION INC | 2,048,757 | 3.1M $ | |
| 9 | Aclaris Therapeutics Inc | 434,455 | 1.6M $ | |
| 10 | MARKER THERAPEUTICS INC | 325,370 | 423K $ | |
| 11 | OnKure Therapeutics Inc | 88,607 | 366.8K $ |